Jean-Francois Pariseau

We develop bispecific antibodies that exploit the potential of the natural immune system. Our Amplify•R platform amplifies and redirects endogenous cytokine signaling instead of recombinant cytokines. We avoid issues such as systemic toxicity, immunogenicity and manufacturing concerns.

Stereo Biotherapeutics is focused on overcoming the challenge of heterogeneity in solid tumours and other diseases. Stereo was incubated and launched by Amplitude Ventures’ Pre-Amp Venture Studio.

Our vision is to develop a pipeline of 1st- in-class precision drug conjugates that are more efficacious and significantly less toxic than traditional antimitotic or topoisomerase inhibiting ADCs.

Thryv Therapeutics Inc. (previously LQT Therapeutics Inc.) is a privately owned company based in Montreal, Quebec, Canada. Thryv Therapeutics is pioneering a precision medicine approach to treat genetic and drug-induced Long QT Syndromes, atrial fibrillation, and resistant cancers with potent and selective inhibitors of Serum Glucocorticoid inducible Kinase. For more information, please visit www.thryvtrx.com.

Giiant is a preclinical-stage biotech company, with its proprietary Precision Delivery technology platform, designs gut-restricted, tissue-specific, small molecule, drug therapeutics with various biological targets in gastroenterology. Its lead program GT-2108 is a microbiota-activated PDE4 inhibitor prodrugs, with improved drug tolerability and enhanced therapeutic effect.

We are creative minds reimagining healthcare. Evidens enables collaborative AI by providing outcome-based structured clinical data and federated learning capabilities across multiple sources and researchers, to truly enable AI-driven discovery at scale. RESEARCH Imagia’s Evidens Platform transforms routine clinical patient data, designed to deliver care, into outcome-based structured information appropriate for AI biomarker discovery. It is purpose-designed for clinical researchers and healthcare partners to use AI and validate clinical insights without needing to be AI experts. COMMERCIALIZATION Imagia Healthcare delivers AI clinical solutions to our B2B partners, as R&D tools, digital health products, or fully regulated software-as-medical-devices validated through our ISO13485 MDSAP certified quality system.

Hearing Testing. Evolved. Think Outside of the Booth

AN INSIDE OUT APPROACH TO PROSTATE ABLATION Profound Medical is a Canadian medical device company that has developed a unique and minimally invasive procedure to ablate the prostate gland in prostate cancer patients. Profound’s novel technology combines real-time MR imaging with transurethral therapeutic ultrasound and closed-loop thermal feedback control. It provides a highly precise treatment tailored to patient-specific anatomy and pathology. This method of prostate ablation offers short treatment times and low morbidity, allowing for fast patient recovery. For more information, visit profoundmedical.com

Angiochem is a clinical-stage biotechnology company discovering and developing novel drugs that are crossing the blood-brain barrier to treat brain diseases. These new Engineered Peptide Compounds (EPiC) have the potential to address significant medical needs, many of which cannot be effectively addressed due to the fundamental physiological challenge the blood-brain barrier presents for therapeutic intervention. Angiochem is developing a deep and broad product pipeline, including small and large molecules, for the treatment of a wide range of brain diseases including brain cancers, lysosomal storage disorders, pain and others. The EPiC platform has been strongly validated in humans.

We develop bispecific antibodies that exploit the potential of the natural immune system. Our Amplify•R platform amplifies and redirects endogenous cytokine signaling instead of recombinant cytokines. We avoid issues such as systemic toxicity, immunogenicity and manufacturing concerns.

Fluid Biomed is a medical device start-up founded by two neurosurgeons at the University of Calgary that has developed an implantable dissolving stent to divert blood flow and heal blood vessels. The desire to innovate and create positive change has always been a priority for the founders and inventors, Dr. John Wong and Dr. Alim Mitha. Working together for the past 18 years to help people with stroke, their drive and commitment to improve patient health sparked a vision to create a radical new stent to cure brain aneurysms without invasive surgery.

Stereo Biotherapeutics is focused on overcoming the challenge of heterogeneity in solid tumours and other diseases. Stereo was incubated and launched by Amplitude Ventures’ Pre-Amp Venture Studio.

Our vision is to develop a pipeline of 1st- in-class precision drug conjugates that are more efficacious and significantly less toxic than traditional antimitotic or topoisomerase inhibiting ADCs.

As the voice of Canada’s private capital industry, the Canadian Venture Capital and Private Equity Association (CVCA) works with the investors behind some of the biggest innovations fuelling the Canadian economy. We are focused on broadening industry awareness through market research and networking opportunities so that our members can make the best decisions for their investments. We also advocate on behalf of the industry to ensure sound public policy that encourages a favourable environment for investment. The CVCA is proud of its track record of delivering value to its members. With this support, our members excel at driving economic growth, creating jobs, and fostering healthy communities.